Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q3 Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q2 Report applies the latest data to analyze the current landscape in life sciences deals.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2025 Q1 Report applies the latest data to analyze the current landscape in life sciences deals.
Locust Walk analyzed the evolving landscape of China’s biotech out-licensing market and its impact on global dealmaking.
Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings.
Life sciences firm Locust Walk’s plans for its $175M SPAC Geoff Meyerson co-founded Locust Walk, a Boston-based life sciences consulting
The Covid-19 pandemic was the biggest biopharma news of 2020. It may be hard to remember now, but in March of last year, biotech indices had quickly nose-dived, along with the broader market, as the reality of the pandemic became apparent. The prevailing financial sentiment was doom and gloom.
Q3 2020 Report: Global Trends in Biopharma Transactions Each quarter our team at Locust Walk compiles key statistics and trends on strategic